Work

First case report of perioperative immunochemotherapy with envafolimab in pulmonary large-cell neuroendocrine carcinoma

Year: 2026
Type: article
Study design: Case Report
Abstract: Pulmonary large-cell neuroendocrine carcinoma (PLCNEC) is a rare and highly aggressive cancer with no standardized perioperative treatment. This study aimed to explore the efficacy and safety of perioperative immunochemotherapy with envafolimab for resectable PLCNEC. We report a 67-year-old male patient with stage IIIA PLCNEC (cT4N0M0) who received four cycles of neoadjuvant immunochemotherapy (envafolimab + carboplatin + etoposide), followed by radical surgery and adjuvant therapy. After neoadjuvant treatment, the tumor shrank by 48.1% and achieved partial response. The patient underwent successful R0 resection and achieved major pathological response. As of May 2025, the patient remained disease-free for 29 months postoperatively, with no grade greater than or equal to 3 adverse events. Notably, clinical benefit was achieved despite negative programmed death-ligand 1 (PD-L1) expression. Perioperative immunochemotherapy with envafolimab is a promising therapeutic option for patients with resectable PLCNEC, even in those with negative PD-L1 expression.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7236632096
FWCI:
Cites: 14
Cited by:
Related to: 10